Peter HodsonOmnix BiopharmaceuticalsOMRITOP PICKNov 20, 2006

Using plasma to stop bleeding in the surgical applications. 200% growth. Sells at about 20 X earnings. Management owns a big chunk. Just reported stellar numbers. Will ultimately get taken over.

Peter Hodson

Owned

Unlock Rating

$29.84

Stock price when the opinion was issued

biotechnologypharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

PAST TOP PICK

(A Top Pick Nov 20/06. Up 30%.) Missed a quarter and there were competitive threats so he got out and missed the upswing.

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Richard Orrell

RN Croft Financial Group

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Peter HodsonOmnix BiopharmaceuticalsOMRITOP PICKNov 20, 2006

You might be interested:

Omnix Biopharmaceuticals(OMRI)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals